This article has been updated to correct information on the firm's tests.

NEW YORK (GenomeWeb News) – Cancer Genetics anticipates raising up to about $49 million in its initial public offering, the genomics-based test development company said in an amended Form S-1 filed last week with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.